First Affirmative Financial Network Buys 64 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Affirmative Financial Network grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 288 shares of the biopharmaceutical company’s stock after purchasing an additional 64 shares during the quarter. First Affirmative Financial Network’s holdings in Regeneron Pharmaceuticals were worth $205,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $683.08 on Friday. The firm has a market cap of $75.06 billion, a PE ratio of 16.90, a P/E/G ratio of 1.62 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $723.36 and a two-hundred day simple moving average of $928.61.

Analyst Ratings Changes

Several equities analysts have commented on REGN shares. Oppenheimer lowered their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.